Leif Johansson said that AstraZeneca had discussed the takeover bid with shareholders throughout May, and was “reasonably happy” that its decision to reject the deal was the right one.
Pfizer has pursued its U.K. rival for months, in its attempt to create the world’s largest drugs company. On Monday, AstraZeneca’s rejected the U.S. giant’s “final” bid of £69 billion ($116 billion), worth £55 per share.
This is developing news story. Please check back for updates.